GURUFOCUS.COM » STOCK LIST » Technology » Software » Enfusion Inc (NYSE:ENFN) » Definitions » Total Payout Ratio

Enfusion (Enfusion) Total Payout Ratio : 0.00 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Enfusion Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Enfusion's current Total Payout Ratio is 0.00.


Enfusion Total Payout Ratio Historical Data

The historical data trend for Enfusion's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enfusion Total Payout Ratio Chart

Enfusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
5.41 20.01 0.60 - -1.87

Enfusion Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enfusion's Total Payout Ratio

For the Software - Application subindustry, Enfusion's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enfusion's Total Payout Ratio Distribution in the Software Industry

For the Software industry and Technology sector, Enfusion's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Enfusion's Total Payout Ratio falls into.



Enfusion Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Enfusion's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 17.322 + 0) / 9.253
=-1.87

Enfusion's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -0.761
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enfusion Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Enfusion's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enfusion (Enfusion) Business Description

Traded in Other Exchanges
N/A
Address
125 South Clark Street, Suite 750, Chicago, IL, USA, 60603
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Executives
Deirdre Somers director C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Bradley Herring officer: Chief Financial Officer C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109
Oleg Movchan director, 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603
Bronwen Bastone officer: Chief People Officer C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603
Stephen Malherbe 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Dan Groman officer: Chief Technology Officer C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603
Tarek Hammoud 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603
Ftv Investment Holdings, L.p. 10 percent owner 601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108
Michael Spellacy director 399 PARK AVENUE, NEW YORK NY 10022
Quiet Light Securities, Llc 10 percent owner 70 WEST MADISON, SUITE 1675, CHICAGO IL 60602
Steven M. Bachert officer: Chief Revenue Officer C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603
Lra Ventures, Llc 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Hillhouse Investment Management, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Roy Luo director 394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111
Iconiq Strategic Partners V-b, L.p. 10 percent owner 394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111

Enfusion (Enfusion) Headlines

From GuruFocus

Enfusion Names Oleg Movchan as Chief Executive Officer

By Business Wire Business Wire 12-22-2022

Enfusion Announces First Quarter 2022 Earnings Release Date

By Business Wire Business Wire 04-29-2022

Enfusion to Present at Upcoming Investor Events

By Business Wire Business Wire 05-02-2022

Enfusion Announces First Quarter 2023 Results

By Business Wire Business Wire 05-09-2023

Enfusion Announces Second Quarter 2023 Results

By Business Wire 08-08-2023

Enfusion Appoints Oleg Movchan Interim Chief Executive Officer

By Business Wire Business Wire 08-22-2022

Enfusion Announces Date of Fourth Quarter and Full Year 2022 Results

By Business Wire Business Wire 02-09-2023